Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses

Abstract

The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

1 . An isolated nucleic acid molecule selected from the group consisting of:
 a) a nucleic acid molecule having a nucleotide sequence which is at least 90% identical to the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof;   b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438;   c) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, wherein the fragment comprises at least 10 consecutive amino acid residues of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438;   d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, wherein the fragment comprises consecutive amino acid residues corresponding to at least half of the full length of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438; and   e) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, wherein the nucleic acid molecule hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof under stringent conditions.   
     
     
         2 . The isolated nucleic acid molecule of  claim 1 , which is selected from the group consisting of:
 a) a nucleic acid having the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof; and   b) a nucleic acid molecule which encodes a polypeptide having the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof.   
     
     
         3 . The nucleic acid molecule of  claim 1 , further comprising vector nucleic acid sequences. 
     
     
         4 . The nucleic acid molecule of  claim 1  further comprising nucleic acid sequences encoding a heterologous polypeptide. 
     
     
         5 . A host cell which contains the nucleic acid molecule of  claim 1 . 
     
     
         6 . The host cell of  claim 5  which is a mammalian host cell. 
     
     
         7 . A non-human mammalian host cell containing the nucleic acid molecule of  claim 1 . 
     
     
         8 . An isolated polypeptide selected from the group consisting of:
 a) a fragment of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438;   b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof under stringent conditions; and   c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to a nucleic acid consisting of the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof.   
     
     
         9 . The isolated polypeptide of  claim 8  having the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438. 
     
     
         10 . The polypeptide of  claim 8 , wherein the amino acid sequence of the polypeptide further comprises heterologous amino acid residues. 
     
     
         11 . An antibody which selectively binds with the polypeptide of  claim 8 . 
     
     
         12 . A method for producing a polypeptide selected from the group consisting of:
 a) a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438;   b) a polypeptide comprising a fragment of the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, wherein the fragment comprises at least 10 contiguous amino acids of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44, and the amino acid sequence encoded by the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438; and   c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of any of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, or a complement thereof, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes with a nucleic acid molecule consisting of the nucleotide sequence of any of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43, and the nucleotide sequence of any of the clones deposited as ATCC® Accession numbers 98999, 98899, 207045, 207046, 207222, PTA-34, PTA-34, PTA-224, PTA-293, PTA-292, PTA-295, PTA-294, PTA-424, and PTA-438, or a complement thereof under stringent conditions;   the method comprising culturing the host cell of  claim 5  under conditions in which the nucleic acid molecule is expressed.   
     
     
         13 . A method for detecting the presence of a polypeptide of  claim 8  in a sample, comprising:
 a) contacting the sample with a compound which selectively binds with a polypeptide of  claim 8 ; and   b) determining whether the compound binds with the polypeptide in the sample.   
     
     
         14 . A kit comprising a compound which selectively binds with a polypeptide of  claim 8  and instructions for use. 
     
     
         15 . A method for detecting the presence of a nucleic acid molecule of  claim 1  in a sample, comprising the steps of:
 a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes with the nucleic acid molecule; and   b) determining whether the nucleic acid probe or primer binds with a nucleic acid molecule in the sample.   
     
     
         16 . A method for identifying a compound which binds with or modulates the activity a polypeptide of  claim 8  comprising the steps of:
 a) contacting a polypeptide, or a cell expressing a polypeptide of  claim 8  with a test compound; and   b) determining whether the polypeptide binds with the test compound or determining the effect of the test compound on the activity of the polypeptide;   
       to thereby identify a compound which binds with or modulates the activity of the polypeptide. 
     
     
         17 . A method for modulating the activity of a polypeptide of  claim 8  comprising contacting a polypeptide or a cell expressing a polypeptide of  claim 8  with a compound which binds with the polypeptide in a sufficient concentration to modulate the activity of the polypeptide. 
     
     
         18 . A method of making an antibody substance which selectively binds with the polypeptide of  claim 8 , the method comprising providing the polypeptide to an immunocompetent vertebrate and thereafter harvesting from the vertebrate blood or serum comprising the antibody substance. 
     
     
         19 . The isolated nucleic acid of  claim 1 , wherein the isolated nucleic acid comprises a portion having the nucleotide sequence of one of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, and 43. 
     
     
         20 . The isolated polypeptide of  claim 8 , wherein the amino acid sequence of the isolated polypeptide is one of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, and 44.